BiotechTube

SCH 900460

Pre-clinicalCompleted
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Psychosis

Conditions

Psychosis

Trial Timeline

Apr 1, 2007 → Jan 1, 2009

NCT ID
NCT00780585

About SCH 900460

SCH 900460 is a pre-clinical stage product being developed by Merck for Psychosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00780585. Target conditions include Psychosis.

What happened to similar drugs?

3 of 17 similar drugs in Psychosis were approved

Approved (3) Terminated (1) Active (14)
✅ZiprasidonePfizerApproved
✅ziprasidone + Standard therapyPfizerApproved
✅PimavanserinAcadia PharmaceuticalsApproved
🔄Paliperidone ERJohnson & JohnsonPhase 3
🔄Quetiapine FumarateAstraZenecaPhase 3
🔄Quetiapine fumarate (Seroquel) SRAstraZenecaPhase 3
🔄Quetiapine fumarate (Seroquel) SRAstraZenecaPhase 3

Hype Score Breakdown

Clinical
3
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00780585Pre-clinicalCompleted

Competing Products

20 competing products in Psychosis

See all competitors
ProductCompanyStageHype Score
Paliperidone ERJohnson & JohnsonPhase 3
40
Saracatinib + Placebo Oral TabletAstraZenecaPhase 1
25
Quetiapine FumarateAstraZenecaPhase 3
40
Quetiapine fumarate (Seroquel) SRAstraZenecaPhase 3
40
Quetiapine fumarate (Seroquel) SRAstraZenecaPhase 3
40
ZiprasidonePfizerApproved
43
ziprasidone + Standard therapyPfizerApproved
35
ziprasidonePfizerPre-clinical
26
Xanomeline/trospiumBristol Myers SquibbPhase 3
47
Memantine + PlaceboLundbeckPhase 1
33
Haloperidol 10 mg Tablets (Cord Laboratories) + Haldol 10 mg Tablets (McNeil Pharmaceuticals)Sandoz GroupPhase 1
26
Cannabidiol (CBD) + PlaceboJazz PharmaceuticalsPhase 3
44
Pimavanserin tartrate (ACP-103) + Pimavanserin tartrate (ACP-103) + PlaceboAcadia PharmaceuticalsPhase 3
37
PimavanserinAcadia PharmaceuticalsApproved
40
pimavanserin tartrate + placeboAcadia PharmaceuticalsPhase 3
37
Placebo + Pimavanserin 34 mg + Pimavanserin 20 mgAcadia PharmaceuticalsPhase 3
37
ACP-204 + PlaceboAcadia PharmaceuticalsPhase 2/3
42
pimavanserin tartrate (ACP-103)Acadia PharmaceuticalsPhase 2
32
Pimavanserin tartrate + PlaceboAcadia PharmaceuticalsPhase 2
32
ACP-204Acadia PharmaceuticalsPhase 3
44